Carvedilol: A new paradigm for the treatment of congestive heart failure

Expert Opinion on Investigational Drugs

Volumn 5, Issue 11, 1996, Pages 1523-1529

  Bril, A ^a   Feuerstein, G Z ^a   Ruffolo R R , Jr ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIOXIDANT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL;

ANGINA PECTORIS; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; HEART PROTECTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; QUALITY OF LIFE; REVIEW;

EID: 0029906154     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.5.11.1523     Document Type: Review

References (0)